These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 18614749)

  • 1. Tigecycline for the treatment of Acinetobacter infections: a case series.
    Gallagher JC; Rouse HM
    Ann Pharmacother; 2008 Sep; 42(9):1188-94. PubMed ID: 18614749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii.
    Schafer JJ; Goff DA; Stevenson KB; Mangino JE
    Pharmacotherapy; 2007 Jul; 27(7):980-7. PubMed ID: 17594203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid development of Acinetobacter baumannii resistance to tigecycline.
    Reid GE; Grim SA; Aldeza CA; Janda WM; Clark NM
    Pharmacotherapy; 2007 Aug; 27(8):1198-201. PubMed ID: 17655518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens.
    Poulakou G; Kontopidou FV; Paramythiotou E; Kompoti M; Katsiari M; Mainas E; Nicolaou C; Yphantis D; Antoniadou A; Trikka-Graphakos E; Roussou Z; Clouva P; Maguina N; Kanellakopoulou K; Armaganidis A; Giamarellou H
    J Infect; 2009 Apr; 58(4):273-84. PubMed ID: 19344841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of tigecycline as a therapeutic option against multidrug-resistant Acinetobacter spp.
    Eser OK; Ergin A; Tunçkanat F; Hasçelik G
    New Microbiol; 2008 Oct; 31(4):535-42. PubMed ID: 19123310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.
    Koomanachai P; Kim A; Nicolau DP
    J Antimicrob Chemother; 2009 May; 63(5):982-7. PubMed ID: 19279050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of tigecycline in the control of a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit.
    Jamal W; Salama M; Dehrab N; Al Hashem G; Shahin M; Rotimi VO
    J Hosp Infect; 2009 Jul; 72(3):234-42. PubMed ID: 19493588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: susceptibility and clinical outcome.
    Kim NH; Hwang JH; Song KH; Choe PG; Kim ES; Park SW; Kim HB; Kim NJ; Park WB; Oh MD
    Scand J Infect Dis; 2013 Apr; 45(4):315-9. PubMed ID: 23113680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report.
    Peleg AY; Potoski BA; Rea R; Adams J; Sethi J; Capitano B; Husain S; Kwak EJ; Bhat SV; Paterson DL
    J Antimicrob Chemother; 2007 Jan; 59(1):128-31. PubMed ID: 17082201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan.
    Liu JW; Wang LS; Cheng YJ; Hsu GJ; Lu PL; Liu YC; Chen CM; Lee CM; Sun W; Jang TN; Chiang PC; Chuang YC; Lin HC; Shi ZY; Kung HC; Huang CH; Tsao SM; Lu CT; Liao CH; Hsueh PR
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S188-91. PubMed ID: 19013353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis.
    Ray L; Levasseur K; Nicolau DP; Scheetz MH
    Ann Pharmacother; 2010 Mar; 44(3):582-6. PubMed ID: 20179255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections.
    Metan G; Alp E; Yildiz O; Percin D; Aygen B; Sumerkan B
    J Chemother; 2010 Apr; 22(2):110-4. PubMed ID: 20435570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series.
    Pastewski AA; Caruso P; Parris AR; Dizon R; Kopec R; Sharma S; Mayer S; Ghitan M; Chapnick EK
    Ann Pharmacother; 2008 Sep; 42(9):1177-87. PubMed ID: 18664609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study.
    Lee NY; Wang CL; Chuang YC; Yu WL; Lee HC; Chang CM; Wang LR; Ko WC
    Pharmacotherapy; 2007 Nov; 27(11):1506-11. PubMed ID: 17963460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
    Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G
    Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bloodstream infections caused by Acinetobacter species with reduced susceptibility to tigecycline: clinical features and risk factors.
    Park GE; Kang CI; Cha MK; Cho SY; Seok H; Lee JH; Kim JY; Ha YE; Chung DR; Peck KR; Lee NY; Song JH
    Int J Infect Dis; 2017 Sep; 62():26-31. PubMed ID: 28676346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
    Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
    Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure.
    Liou BH; Lee YT; Kuo SC; Liu PY; Fung CP
    Antimicrob Agents Chemother; 2015; 59(6):3637-40. PubMed ID: 25824230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of tigecycline against clinical isolates of multidrug-resistant Acinetobacter baumannii in Siriraj Hospital, Thailand.
    Tiengrim S; Tribuddharat C; Thamlikitkul V
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S102-5. PubMed ID: 17718251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.